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ABSTRACT
HOX family members encode transcription factors crucial for embryogenesis and 
may be associated with carcinogenesis. Here, we evaluated the expression of 39 HOX 
genes in cervical cancer by using clinicopathological information and gene expression 
data of 308 patients from The Cancer Genome Atlas (TCGA) database. Correlations 
between mRNA expression of HOX family members and clinicopathological variables 
were explored. Seventy-three (23.7%) patients died during the follow-up period 
(median, 22.0 months). Overall mortality was significantly associated with advanced 
FIGO stage, lymph node metastasis, lymphovascular invasion, and increased HOXA1, 
HOXA5, HOXA6, and HOXC11 mRNA expression. Kaplan–Meier survival analysis 
revealed that overall survival was significantly shorter in patients with high HOXA 
rather than low HOXA expression (HOXA1, P = 0.012; HOXA5, P = 0.008; and HOXA6, 
P = 0.006). Upregulated HOXA1, HOXA5, and HOXA6 expression are significantly 
correlated with unfavorable overall survival and increased mortality in cervical 
cancer patients. Therefore, HOXA expression is a potential cervical cancer prognostic 
indicator.
INTRODUCTION
Cervical cancer is a multifactorial disease caused 
due to genetic, environmental, and epigenetic factors, as 
well as infection by human papillomavirus [1]. Recently, 
alterations in the expression of transcription factors have 
been focused upon for its importance in the development 
of this malignancy.
A large amount of scientific evidence indicates that 
the expression levels of many genes involved in normal 
embryo development are aberrant in and contribute to 
carcinogenesis [2]. Homeobox (HOX) genes encode 
homeoproteins, which function as transcription factors 
in the differentiation and proliferation processes at the 
time of development of embryonic structures, and their 
aberrant expression has been found to be associated with 
carcinogenesis and aggressiveness [3, 4]. HOX genes 
were first described as factors involved in embryogenesis 
in the fruit fly, Drosophila melanogaster [5]. HOX genes 
commonly share a 120-base pair DNA sequence called the 
homeobox, which codes a 61-amino acid peptide termed 
as the homeodomain. This domain has been characterized 
previously using nuclear magnetic resonance spectroscopy 
[6, 7]. HOX genes and their protein structures have also 
been found in humans [8, 9]. In the human genome, there 
are 39 HOX genes located on four different chromosomes, 
and these genes are the structural and functional homologs 
of the homeotic complex of Drosophila [10].
Previous studies have reported that upregulation of 
the HOX gene is related to adverse prognostic factors in 
cervical cancer, but the majority of these studies have been 
limited by small sample sizes and have been performed 
only in vitro. Aberrant expression of HOXD9, HOXC5, 
HOXC8, and HOXB2, HOXB4, HOXC10, and HOXD13 
has been found in cervical cancer cell lines [11–13]. A 
recent study focused on the mechanism of HPV16 E7-
mediated epigenetic regulation of HOX genes showed 
the master regulatory role of HPV16 E7 in modulating 
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the expression of HOX cluster genes [14]. Several studies 
have also revealed the potential roles of HOX antisense 
long non-coding RNAs in cervical cancer aggressiveness 
[15–17]. These results suggest that aberrant expression 
of HOX-related genes is associated with the process of 
cervical carcinogenesis.
Therefore, in this study, we aimed to analyze the 
mRNA expression levels of all the 39 HOX genes using 
data from The Cancer Genome Atlas (TCGA) database 
[18]. We then went on to explore their correlations with 
clinical data including survival outcomes in cervical 
cancer and evaluated the prognostic value of HOX gene 
expression analysis. To the best of our knowledge, this is 
the first study to analyze the expression of all HOX genes 
using data from the TCGA database. Our findings indicate 
that measurement of HOX gene expression can help 
predict prognosis and overall survival in cervical cancer.
RESULTS
A total of 308 cervical cancer cases were included 
in this study; of these, 253 were squamous cell carcinoma, 
28 adenocarcinomas, 17 mucinous carcinomas, three 
endometrioid carcinomas, and seven adenosquamous 
carcinoma cases. The median follow-up period was 
22.0 months (range: 0.1–213.6 months). Among the 
clinicopathological features, overall mortality was found 
to be associated with FIGO stage III/IV, lymph node 
metastasis, and lymphovascular invasion (Table 1).
Table 2 shows the correlations between the 
clinicopathological features and the mRNA expression 
levels of HOX family genes. When the cases were 
categorized into low and high mRNA expression groups 
based on cut-off values determined as medians for each 
gene, higher HOXA1, HOXA5, HOXA6, and HOXC11 
expression was found to be associated with increased 
overall mortality (odds ratio (OR): 1.858, 95% confidence 
interval (CI): 1.086–3.178; OR: 2.003, 95% CI: 1.167–
3.438; OR: 2.162, 95% CI: 1.256–3.724; and OR: 1.724, 
95% CI: 1.011–2.942, respectively). High FIGO stage 
also highly correlated with high HOXB7 expression, 
and lymph node metastasis was found to be associated 
with high HOXD12 and HOXD13 expression (P < 0.01). 
Moreover, squamous cell histologic type was found to 
be highly correlated with high expression of HOXA1, 
HOXA4, HOXA7, HOXA9, HOXB2, HOXB3, HOXB5–9, 
HOXC4, HOXC5, HOXC13, HOXD1, HOXD9, HOXD10, 
HOXD11, and HOXD13 (P < 0.001).
Linear regression analysis indicated that overall 
mortality was significantly associated with high mRNA 
expression levels of HOXA1 (t = 3.033, P = 0.003) (Table 
3). High expression of the HOXA1 gene was also found to 
be positively correlated with squamous cell histologic type 
and lymph node metastasis.
In Kaplan–Meier survival analyses, we found that 
groups with higher HOXA1, HOXA5, and HOXA6 mRNA 
expression levels had significantly unfavorable overall 
survival than those with a lower level of expression 
of these genes (P = 0.012, P = 0.008, and P = 0.006, 
respectively) (Figure 1).
DISCUSSION
In this study, we showed that the increased mRNA 
expression of four HOX genes—HOXA1, HOXA5, 
HOXA6, and HOXC11—is independently associated with 
mortality in cervical cancer based on data from TCGA 
[18]. Several HOX genes were shown to be correlated 
with risk factors for poor prognoses including advanced 
FIGO stage, high grade, lymph node metastasis, and 
lymphovascular invasion. Interestingly, high expression 
of most of the HOX genes was found to be strongly 
associated with squamous cell type histology. In particular, 
the upregulation of the HOXA1, HOXA5, and HOXA6 
genes were found to be significantly associated with 
unfavorable overall survival in patients with cervical 
cancer.
Cancers have been revealed as aberrations in 
the growth, differentiation, and organization of cell 
populations [19]. These basic processes are supposed to be 
tightly coordinated and controlled during embryogenesis 
as well as in adult tissues [20]. The oncogerminative 
theory of cancer development suggests that malignant 
transformation occurs due to the aberrant expression of 
development-related genes [21]. According to this concept, 
carcinogenesis is a dynamic self-organizing process that 
resembles the process of early embryo development. The 
malignant transformation that arises from gene mutations 
in combination with epigenetic dysregulation eventually 
results in reprogramming of somatic cells into immortal 
cells that simulate germline cells, which is consistent with 
the characteristics of cancer stem cells or, in other words, 
oncogerminative cells.
As a developing malignant transformation, the 
oncogerminative cell is considered to follow the same 
biological principles as those in play in a germline cell 
as it develops into a blastocyst-stage embryo [21]. 
The oncogerminative theory of cancer development 
hypothesizes that to have a cancer is the same as 
gestating a damaging embryo. This oncogerminative 
hypothesis of tumor growth includes five stages of tumor 
development: (i) malignant transformation of normal cells 
into oncogerminative cells, i.e. cancer stem cells; (ii) 
reproduction of the oncogerminative cells; (iii) formation 
of a multicellular spheroid (a parody of blastocyst 
formation) characterized by a heterogeneous population 
of cells in addition to the oncogerminative cells; (iv) 
vascularization of the oncospheroid and its growth; and (v) 
development of the majority of malignant tumors together 
with disaggregation of the oncogerminative cells, their 
migration into the organism’s tissues, and development of 
metastatic foci of tumor growth [22].
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A considerable body of evidence has proven the 
crucial role of HOX genes as developmental genes during 
embryogenesis as well as the critical role of aberrant HOX 
gene expression in the development of various tumors 
[2–4]. However, to the best of our knowledge, our study 
is the first one to be based on TCGA data and reporting 
the correlation between upregulated HOX gene expression 
and aggressiveness of cervical carcinoma. Nevertheless, 
further studies are needed in the future to fully understand 
the role of HOX genes in cervical cancer.
Our results also indicate that the analysis of HOX 
gene expression, especially in cytological or surgical 
specimens, can help identify patients with cervical cancer 
who are expected to have a poor prognosis. According to 
the results of the analysis, we can then recommend more 
aggressive treatments or more frequent follow-ups for 
such cases with high risk. Furthermore, novel therapeutic 
agents need to be developed for refractory cervical 
cancer patients administered standard treatment. Our 
results highlighting the correlation between HOX gene 
upregulation and poor survival outcomes indicate that 
drugs inhibiting HOXA gene expression could have the 
ability to induce the inhibition of oncogerminative cells 
and thus help in the treatment of refractory cervical cancer 
patients. In fact, one previous in vitro study has shown 
the potential of the use of a homeobox transcription factor 
inhibitor in this respect [23].
One major limitation of this study is the short-
term follow-up period; the small number of mortalities 
observed during this period might weaken the 
clinical applicability of the current findings. A more 
comprehensive investigation based on regularly updated 
Table 1: Correlation between clinicopathological features and overall mortality
Variables Dead, n=73 (%) Alive, n=235 (%) P value
Age
<45 26 (35.6) 110 (46.8) 0.093
≥45 47 (64.4) 125 (53.2)
Stage
I/II 48 (65.8) 185 (81.5) 0.005
III/IV 25 (34.2) 42 (18.5)
Histology
Squamous Cell 62 (84.9) 191 (81.6) 0.733
Adenocarcinoma 5 (6.8) 23 (9.8)
Mucinous 5 (6.8) 12 (5.1)
Endometrioid 0 3 (1.3)
Adenosquamous 1 (1.4) 5 (2.1)
Grade
1, 2 40 (63.5) 115 (54.0) 0.182
3, 4 23 (36.5) 98 (46.0)
ECOG
0,1 39 (90.7) 156 (95.7) 0.246
2,3 4 (9.3) 7 (4.3)
LN metastasis
Yes 19 (54.3) 35 (27.3) 0.003
No 16 (45.7) 93 (72.7)
LVI
Yes 25 (92.6) 58 (45.3) <0.001
No 2 (7.4) 70 (54.7)
ECOG, The Eastern Cooperative Oncology Group performance score; LN, lymph node; LVI, lymphovascular invasion.
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Table 2: Summary of the correlation between clinicopathological features and mRNA expression counts of homeobox 
(HOX) family genes
Age≥45 Stage III/IV Squamous cell Grade 
3/4
ECOG 
2/3 LN metastasis LVI Mortality
HOXA1 +++ +
HOXA2 + +
HOXA3
HOXA4 +++
HOXA5 ++ ++
HOXA6 + ++
HOXA7 +++
HOXA9 +++
HOXA10
HOXA11 +
HOXA13
HOXB1 +
HOXB2 +++
HOXB3 + +++
HOXB4 ++
HOXB5 +++ +
HOXB6 +++ +
HOXB7 ++ +++
HOXB8 + +++
HOXB9 + +++ +
HOXB13 +
HOXC4 +++
HOXC5 ++ +++
HOXC6 ++ +
HOXC8 ++ +
HOXC9
HOXC10 ++
HOXC11 + + + +
HOXC12
HOXC13 +++
HOXD1 +++
HOXD3 ++ +
HOXD4 +
HOXD8 + +
HOXD9 + +++ + +
HOXD10 +++ +
HOXD11 +++ +
HOXD12 + ++
HOXD13 +++ ++ +
+, correlation with P value < 0.05; ++, correlation with P value <0.01; +++, correlation with P value < 0.001; ECOG, The 
Eastern Cooperative Oncology Group performance score; LN, lymph node; LVI, lymphovascular invasion.
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Figure 1: Kaplan-Meier survival analysis of 308 cervical cancer patients stratified by (A) HOXA1, (B) HOXA5, (C) HOXA6, and (D) 
HOXC11 gene expression levels.
Table 3: Linear regression analysis between clinicopathological features and mRNA expression count of HOXA1, 
HOXA5, HOXA6, and HOXC11
HOXA1 HOXA5 HOXA6 HOXC11
t value P value t value P value t value P value t value P value
Age≥45 -1.379 0.172 0.081 0.936 -0.822 0.413 0.477 0.635
Stage III/IV -0.927 0.357 0.176 0.861 -0.066 0.948 -0.412 0.682
Squamous cell 4.536 <0.001 1.718 0.09 -0.138 0.891 -2.94 0.004
Grade ¾ 1.567 0.121 -0.076 0.94 -0.917 0.362 -1.099 0.275
ECOG 2/3 0.358 0.721 1.458 0.149 1.585 0.117 -0.449 0.655
LN metastasis 1.907 0.06 -0.233 0.816 0.931 0.355 0.675 0.501
LVI -1.403 0.165 -0.828 0.41 -0.12 0.905 0.137 0.891
Mortality 3.033 0.003 0.709 0.48 1.209 0.23 -0.23 0.819
ECOG, The Eastern Cooperative Oncology Group performance score; LN, lymph node; LVI, lymphovascular invasion.
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TCGA data is required in the future. Nevertheless, this 
study proved the hypothesis that overexpression of HOXA 
genes is associated with poor prognosis in cervical cancer, 
based on data obtained using the RNA-seq technique. 
However, further validation using a different modality 
such as a microarray or immunohistochemical assay with 
a large volume might also be needed to verify the results 
of the present study.
In conclusion, in this study, we showed that the 
upregulation of the expression of the HOXA1, HOXA5, 
and HOXA6 genes are significantly associated with 
unfavorable overall survival as well as increased mortality 
in a large cohort of cervical cancer cases from TCGA 
database. Our results indicate that the evaluation of HOXA 
gene expression may be valuable for predicting prognosis 
in cervical carcinoma. Also, we could consider HOX 
gene expression levels may have a potential for use as 
biomarkers for the same purpose.
MATERIALS AND METHODS
Data acquisition
We obtained mRNA expression counts for 39 HOX 
family genes and the corresponding clinicopathological 
information from the TCGA data portal (https://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp). The personal 
information of the patients is anonymized, and the patients 
were deidentified. According to TCGA publication 
guidelines (http://cancergenome.nih.gov/publications/
publicationguidelines), these mRNA sequencing data have 
no restrictions on publication, and no additional approval 
by an ethics committee was required to publish the use of 
the data.
The Illumina Genome Analyzer was utilized as the 
platform for DNA sequencing (Illumina Inc, San Diego, 
CA). RNA sequencing data were obtained using Illumina 
HiSeq 2000 RNA Sequencing Version 2 analysis, and the 
mRNA expression counts were expressed as RNA-Seq 
data normalized to data from the pan-cancer database.
Patients
We collected mRNA expression data for 39 
HOX family genes for each patient, along with their 
clinicopathological features including age at initial 
pathologic diagnosis, FIGO (The International 
Federation of Gynecology and Obstetrics) stage, 
histologic subtype, ECOG (Eastern Cooperative 
Oncology Group) performance score, lymph node 
metastasis, lymphovascular invasion, and overall survival 
(Supplementary Table 1).
Statistical analyses
We used the Fisher exact or χ2 tests for categorical 
variables according to sample size. Linear regression 
was applied to assess the associations between clinical 
variables and the expression counts of each HOX gene. 
We also evaluated t values for correlation coefficients. 
Median of HOX gene expression was determined as a 
cut-off value for the prediction of survival. Kaplan-Meier 
survival analyses based on calculated cut-off values were 
performed. SPSS version 23.0 (IBM Corp., Armonk, NY, 
USA) was used for data analysis.
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